Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. ... Read more
The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV) patients, but it seems to be associated with a higher relapse ... Read more
Disease status at three and six months seems to predict long-term survival and kidney failure in patients with ANCA-associated vasculitis (AAV), a study shows. These findings suggest that early disease ... Read more
The U.S. Food and Drug Administration has approved a label update for Rituxan (rituximab) to include information for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who ... Read more
Patients with small-vessel vasculitides, including ANCA-associated vasculitis, are more likely to need aggressive treatments or to die in the intensive care unit (ICU) than patients with other systemic autoimmune diseases, ... Read more
Patients with ANCA-associated vasculitis (AAV) are more likely to exhibit severe disease and experience poor kidney outcomes if they have low levels of the C3 complement protein at diagnosis, ... Read more
Pin It on Pinterest